This review covers the medical options for malignant gliomas based on the results of recent clinical trials and updated information on molecular markers of prognostic and predictive value. In addition to alkylating agents, the antiangiogenic drug bevacizumab is increasingly used, particularly in cases of recurrence. Supportive care, including antiedema agents, antiepileptic drugs and anticoagulants, represent complementary treatment approaches of the utmost clinical importance.
Pharmacologic therapies for malignant glioma: a guide for clinicians.
SOFFIETTI, Riccardo;BERTERO, Luca;PINESSI, Lorenzo;Rudà R.
2014-01-01
Abstract
This review covers the medical options for malignant gliomas based on the results of recent clinical trials and updated information on molecular markers of prognostic and predictive value. In addition to alkylating agents, the antiangiogenic drug bevacizumab is increasingly used, particularly in cases of recurrence. Supportive care, including antiedema agents, antiepileptic drugs and anticoagulants, represent complementary treatment approaches of the utmost clinical importance.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1419452.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
545.26 kB
Formato
Adobe PDF
|
545.26 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
